Rx License-Rx

TAB-2712

Detection and Differentiation of Pathogenic Fungi in Clinical Samples Using a Multi-Analyte Profiling System

This invention provides a rapid, sensitive and specific diagnostic tool for the detection of pathogenic fungi and subsequent species-specific discrimination. CDC scientists have developed nucleic acid probes to identify the six most medically important Candida species and endemic mycoses, and to differentiate them from other medically important fungi in a multi-analyte profiling system. Candida fungi are one of the leading causes of clinically-acquired bloodstream infections and, although improved antifungal compounds have been recently introduced, they have unique, species-specific treatment responses. This multi-analyte approach has the potential to simultaneously identify up to 100 different fungi in one assay. Additionally, the assay is quite cost effective in terms of resource input, time invested and technician labor. Used in conjunction with contemporary antifungal medications, this assay provides a very rapid and specific...

Intelligence Memo

Owner: National Institutes of Health

Core category: Therapeutics

Therapeutic area: Infectious Disease

Indication: Infectious Disease

Modality: Small Molecule

Focus tags: Infectious Disease

Technology tags: Small Molecule, Diagnostic / Biomarker

Mechanism:

Development stage: Preclinical

Patent status: Abandoned; Expired

Availability: Available for license

Plain-English Licensing Breakdown

This is a license opportunity for a therapeutic asset or drug-enabling technology in Infectious Disease. In plain English, the buyer would be licensing science that could become a treatment program, usually after more validation. The current package appears to be preclinical and is associated with National Institutes of Health. The practical first use case is Infectious Disease. Public description: This invention provides a rapid, sensitive and specific diagnostic tool for the detection of pathogenic fungi and subsequent species-specific discrimination. CDC scientists have developed nucleic acid probes to identify the six most.

What is exciting

Already past pure discovery: Preclinical validation gives a buyer something concrete to reproduce, optimize, or package into an IND-enabling plan.

Can sell into pharma before reimbursement: A biomarker or AI tool can create value as trial enrichment, patient stratification, or translational support before becoming a regulated diagnostic.

The License-Rx pivot is the real unlock: The exciting version is not just the university pitch; it is the focused path: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch

Negatives / diligence concerns

Translation still unproven: Animal or lab data may not predict human performance; tox, PK/PD, CMC, and indication selection still need diligence.

Validation can be harder than the demo: Models and biomarkers need locked datasets, external validation, clinical utility, data rights, and a regulatory/reimbursement plan.

Risk Flags

  • Human validation and clinical path require diligence.
  • Patent scope and remaining exclusivity need review with counsel.
  • Inventor readiness and licensing terms are not yet verified.

Strategic Pharma Attractiveness

Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Infectious Disease wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.

Most logical pharma targets GSK — Vaccines and anti-infective infrastructure. Pfizer — Hospital, anti-infective, and vaccine commercial reach. Johnson & Johnson — Pathogen-focused development and global health channels.

Development Strategy to Increase PoS

First indication: Infectious Disease

Study design: Retrospective locked-dataset validation followed by one prospective pharma enrichment pilot.

Key experiments Validate the AI-optimized pivot: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch Run independent replication of the core claim with pre-specified success criteria Generate a partner-facing risk register that separates solved, testable, and unresolved risks

Final Recommendation

Proceed: Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch

Best next experiment: Run the smallest independent study that validates: Run pathogen-panel susceptibility, resistance mapping, and one translational model before any broad tox spend.

Best licensing timing: Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.